Literature DB >> 23740516

Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling.

Liang Lu1, Cuixian Li, Dong Li, Ying Wang, Chun Zhou, Weiwei Shao, Jin Peng, Yan You, Xinwen Zhang, Xiaoyan Shen.   

Abstract

Malignant gliomas (MGs) are among the most aggressive types of cancers in the human brain. Frequent tumor recurrence caused by a lack of effective therapeutic approaches results in a poor prognosis. Signal transducer and activator of transcription 3 (STAT3), an oncogenic protein, is constitutively activated in MGs and predicts a poor clinical outcome. STAT3 therefore is considered to be a promising target for the treatment of MGs. Cryptotanshinone (CTS), the main bioactive compound from the root of Salvia miltiorrhiza Bunge, has been reported to have various pharmacological effects. However, little is known about its function in MG cells. In this study, we evaluated the effect of CTS on the proliferation of human glioma cell lines (T98G and U87). Our results revealed that CTS significantly suppresses glioma cell proliferation. The phosphorylation of STAT3 Tyr705, but not Ser727, was inhibited by CTS, and STAT3 nuclear translocation was attenuated. Overexpression of constitutively active mutant STAT3C reversed the inhibitory effect of CTS, while knockdown STAT3 showed a similar inhibitory effect as CTS treatment. Following the downregulation of STAT3-regulated proteins cyclinD1 and survivin, cell cycle progression significantly arrested in G1/G0 phase. These results indicate that CTS may be a potential antiproliferation agent for the treatment of MGs and that its mechanism may be related to the inhibition of STAT3 signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23740516     DOI: 10.1007/s11010-013-1711-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  33 in total

Review 1.  Janus kinases: components of multiple signaling pathways.

Authors:  S G Rane; E P Reddy
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

Review 2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

Review 3.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

4.  Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.

Authors:  A Suzuki; M Hayashida; T Ito; H Kawano; T Nakano; M Miura; K Akahane; K Shiraki
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

Review 5.  Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications.

Authors:  Suyun Huang
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

6.  Growth-inhibitory and apoptosis-inducing effects of tanshinones on hematological malignancy cells and their structure-activity relationship.

Authors:  Hui Li; Qing Zhang; Ting Chu; Hua-Yue Shi; Hui-Min Fu; Xiang-Rong Song; Wen-Tong Meng; Sheng-Jun Mao; Yong-Qian Jia
Journal:  Anticancer Drugs       Date:  2012-09       Impact factor: 2.248

Review 7.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells.

Authors:  Dennis W Stacey
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

Review 8.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.

Authors:  Herbert B Newton
Journal:  Expert Rev Anticancer Ther       Date:  2004-02       Impact factor: 4.512

9.  Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells.

Authors:  Dae-Seop Shin; Hye-Nan Kim; Ki Deok Shin; Young Ju Yoon; Seung-Jun Kim; Dong Cho Han; Byoung-Mog Kwon
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

Review 10.  Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.

Authors:  Hui-Wen Lo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

View more
  20 in total

1.  Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis.

Authors:  Byung Gak Kim; Jung-Yoon Yoo; Tae Hoon Kim; Jung-Ho Shin; John F Langenheim; Susan D Ferguson; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Jae-Wook Jeong
Journal:  Hum Reprod       Date:  2015-03-06       Impact factor: 6.918

2.  MicroRNA-122-3p inhibits tumor cell proliferation and induces apoptosis by targeting Forkhead box O in A549 cells.

Authors:  Wen Wang; Jinsong Yang; Fenglei Yu; Wenjie Li; Li Wang; Haoyu Zou; Xia Long
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

3.  MicroRNA-195 suppresses colorectal cancer cells proliferation via targeting FGF2 and regulating Wnt/β-catenin pathway.

Authors:  Xianxiang Zhang; Ji Xu; Tao Jiang; Guangwei Liu; Dongsheng Wang; Yun Lu
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

4.  Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.

Authors:  Peibin Yue; Francisco Lopez-Tapia; David Paladino; Yifei Li; Chih-Hong Chen; Andrew T Namanja; Tyvette Hilliard; Yuan Chen; Marcus A Tius; James Turkson
Journal:  Cancer Res       Date:  2015-06-18       Impact factor: 12.701

5.  Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Nancy H Colburn; Baojin Hua
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

Review 6.  The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

Authors:  Jessica L Geiger; Jennifer R Grandis; Julie E Bauman
Journal:  Oral Oncol       Date:  2015-12-28       Impact factor: 5.337

7.  DLX3-Dependent STAT3 Signaling in Keratinocytes Regulates Skin Immune Homeostasis.

Authors:  Shreya Bhattacharya; Jin-Chul Kim; Youichi Ogawa; Gaku Nakato; Veronica Nagle; Stephen R Brooks; Mark C Udey; Maria I Morasso
Journal:  J Invest Dermatol       Date:  2017-12-12       Impact factor: 8.551

8.  Isocryptotanshinone Induced Apoptosis and Activated MAPK Signaling in Human Breast Cancer MCF-7 Cells.

Authors:  Xuenong Zhang; Weiwei Luo; Wenwen Zhao; Jinjian Lu; Xiuping Chen
Journal:  J Breast Cancer       Date:  2015-06-26       Impact factor: 3.588

9.  IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.

Authors:  Shanzhou Duan; Ying Tsai; Peter Keng; Yongbing Chen; Soo Ok Lee; Yuhchyau Chen
Journal:  Oncotarget       Date:  2015-09-29

10.  Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation.

Authors:  Liang Lu; Sulin Zhang; Cuixian Li; Chun Zhou; Dong Li; Peiqing Liu; Min Huang; Xiaoyan Shen
Journal:  Cell Death Dis       Date:  2017-05-11       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.